Fanny Jaulin co-founded Orakl Oncology in 2023, where she now serves as both President (CEO) and Chief Scientific Officer (CSO). In this dual role, she leverages her deep scientific expertise along with strong connections to the hospital ecosystem and pharmaceutical industry to drive innovation in oncology. Before Orakl, Fanny built Gustave Roussy patient organoid expertise and managed institutional organoid-based programs. Fanny Jaulin holds a PhD in cell biology from Aix-Marseille University and completed postdoctoral research in New York at both the Weill Cornell Medical Center and the Memorial Sloan Kettering Cancer Center.